Headline Closes $865 Million to Invest in Growth-Stage Tech Companies
Headline today announced Headline Global Growth IV with $865M1 of capital committed to the strategy to support companies at their Growth inflection points, Series B and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918812241/en/
Headline's Global Growth Equity Team (Photo: Business Wire)
The Global Growth strategy has three distinct advantages: a diverse and experienced team, extensive geographic coverage, and advanced in-house built technology for sourcing (Searchlight) and analytics (DeepDive). Led by seasoned Growth investor Shalini Rao, the Growth team is committed to identifying and nurturing "Paradiesvögel"—tenacious technology founders poised for global success. Recent team additions to Headline Global Growth include Nancy Xiao, Trevor Neff, Reda Bensaid, Jake Horwitz and Austin Hack, all of whom will work out of Headline’s San Francisco and European offices.
Global Growth IV represents the evolution of growth investing at Headline. Previously, Headline primarily made investments in growth companies where Headline also had early stage exposure, backing standouts like SEMrush, Pismo, Raisin, Segment, and Fetch. With a strategy specifically crafted to capture the inflection points of Growth, Headline is expanding its universe. The fund will seek to deploy capital flexibly, with investments ranging from roughly $20 million to $70 million, mainly focusing on Headline’s core markets in the US and Europe. This approach will allow Headline to capitalize on its history of seeking to back category-leading companies in every major global tech market.
The Global Growth strategy is built on a foundation of Headline's core values and the rigor of world-class growth investing. The firm has developed advanced sourcing technologies, including the proprietary platforms, Searchlight and DeepDive, which enhance the team's ability to connect with founders and analyze business efficiencies. This technology-driven approach enables the team to engage with around 80% of companies that have raised Series A financings each month.
Headline's commitment to fostering close, long-term relationships with entrepreneurs is reflected in its investment philosophy. The firm prioritizes quality over quantity, focusing on a small number of companies to provide high levels of engagement and support.
“An investment firm ultimately builds just one product: its people,” said Rao. “And the team at Headline is united around the single objective of helping entrepreneurs succeed. To do that we will draw on our networks and track records, built up over years in both the US and Europe. But really it’s a mindset: we will do anything and everything we can to help our founders create generational companies. Just like the founders that we hope to back, we hustle and we are hungry.”
“The European tech ecosystem is still in its early stages, with lots of unrealized potential. As we have seen in the past 20 years, venture markets can shift rapidly, but technology as a whole continues growing. AI is transforming every industry and creating a massive reset,” says Christian Leybold, Founding Partner of Headline. “With a decade of track record, a proprietary technology platform, and teams on the ground in major technology hubs, Growth IV arrives at a fitting time to back some of the best private technology companies—regardless of stage.”
As Headline embarks on this next chapter, it remains dedicated to supporting innovative technology companies throughout their lifecycle. With over $4 billion in assets under management, Headline is well-positioned to drive growth and innovation in the technology sector.
The fund includes capital commitments from KfW Capital, the venture subsidiary of the German state-owned investment and development bank KfW, and the European Investment Fund (EIF). Commenting on the raise, Marjut Falkstedt, EIF Chief Executive, says: “Despite being home to world-class talent, cost-efficient companies, and groundbreaking ideas, Europe invests significantly less in venture capital compared to the United States and Asia. This funding gap not only limits our startups' ability to scale but also risks losing them to foreign markets where capital is more readily available. This is a trend that we are committed to reversing, and that is why we are happy to back Headline through the European Tech Champions Initiative.”
Christian Röhle, Head of Investment Management of KfW Capital, commented: “Headline’s $865 million growth fund is a very positive signal for the European VC ecosystem. Large-volume VC funds are indispensable to close the later-stage financing gap in the European VC market. Only large VC funds can lead large financing rounds to support the growth of promising scale-ups. In parallel to its successful closing, Headline attracted two experienced international female investment professionals as partners to its new growth fund, thereby fostering diversity in the European VC ecosystem.”
About Headline
Founded in 1998, Headline is a venture capital firm that partners with fast-growing technology teams in key geographies to make their success global. With more than $4B of assets under management, the firm invests from its network of regionally-focused early-stage funds across the US, Europe, Asia, and Latin America. Headline’s Global Growth Fund invests globally from Series B and beyond. The size and locations of these funds allow the firm to see local trends up close, meet winning founders, and lead rounds at every stage. Among the 300+ investments globally, Headline’s portfolio includes Acorns, AppFolio, ANGI (FKA Angie’s List), Brite Payments, Bumble, Fetch, Gopuff, Honeycomb, LucidLink, Mistral AI, Monta, NGINX, Raisin, Sonos, Segment, SEMrush, Staffbase, Swile.
Headline relies on the “venture capital adviser exemption” for purposes of the Investment Advisers Act of 1940. This press release announces the close of our two parallel funds. No part of this press release is intended to be, and may be relied upon, as investment advice, investment recommendation, an offer to sell, or the solicitation of any offer to buy, any security or adopt any investment strategy. No compensation was paid for any quoted remarks included in this press release. A complete list of Headline’s investments is available at headline.com/portfolio.
1 All amounts that are denominated in EUR (Euros) have been converted to USD (U.S. Dollars) using an exchange rate of 1.1087 the exchange rate as of September 9, 2024. Please note that exchange rates fluctuate, and the conversion rate at the time of actual transactions may differ.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918812241/en/
Contacts
Media Contact:
Jacopo Luperi
Marketing & Communications, Headline
jacopo@headline.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom